The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

One in three women diagnosed with MS will subsequently conceive, therefore consideration of the maternal-infant dyad is ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

Learn more about whether Alvotech or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Neurologist Stephen Hauser, MD, of the University of California San Francisco, and epidemiology professor Alberto Ascherio, ...